IN THE CLAIMS

1. (Currently Amended) A method of treating an individual in need of treatment for a vascular permeability disorder, comprising administering to the individual in need of treatment for a vascular permeability disorder a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol~~a 1,2-aminoalcohol, a pharmaceutically acceptable salt thereof, or a phosphorylated form thereof, having the formula~~



~~wherein $R_1$ is a substituted or unsubstituted straight- or branched-carbon chain having 12 to 22 carbon atoms, and each of $R_3$, $R_3$, $R_4$ and $R_5$ are independently hydrogen or lower alkyl.~~

2-6. (Cancelled).

7. (Previously Presented) The method of Claim 1, wherein the vascular endothelial sphingosine-1-phosphate receptor is $S1P_1$, $S1P_2$, $S1P_3$, $S1P_4$, $S1P_5$, or a combination comprising one or more of the foregoing receptors.

8. (Previously Presented) The method of Claim 7, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist induces adherens junction assembly.

9. (Previously Presented) The method of Claim 1, wherein the vascular permeability disorder is endothelial injury, thrombocytopenia, atherosclerosis, ischemic cardiovascular disease, ischemic peripheral vascular disease, a peripheral vascular disorder associated with diabetes, Dengue hemorrhagic fever, adult (acute) respiratory distress syndrome, vascular leak syndrome, sepsis, autoimmune vasculitis, or a combination comprising one or more of the foregoing disorders.

10-21. (Cancelled) ]

22. (New) A method of treating an individual in need of treatment for adult (acute) respiratory distress syndrome, comprising administering to the individual in need of treatment for a vascular permeability disorder a therapeutically effective amount of a vascular endothelial sphingosine-1-phosphate receptor agonist, wherein the vascular endothelial sphingosine-1-phosphate receptor agonist is 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol.